Nicholas Piramal: New products make up for anti–infective decline - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jul 24, 2000 - Nicholas Piramal: New products make up for anti–infective decline

Nicholas Piramal: New products make up for anti–infective decline

Jul 24, 2000

Despite a 12% degrowth in anti–infectives in the first quarter, Nicholas Piramal has managed to report a 32% growth in bottomline. This was primarily on the back of new introductions such Rejoint (a nutraceutical consumed by arthirtis patients) and Haemaccel and Omnatax which were taken over from Hoechst.

(Rs m)1QFY001QFY01Change
Sales 1,121 1,325 18.2%
Other Income 14 12 -12.5%
Expenditure 938 1,098 17.1%
Operating Profit (EBDIT) 184 227 23.6%
Operating Profit Margin (%)16.4%17.1% 
Interest (net) 43 40  
Depreciation 25 33 32.3%
Profit before Tax13016628.0%
Other Adjustments   
Tax 15 14 -6.7%
Profit after Tax/(Loss) 115 152 32.5%
Net profit margin (%)10.2%11.5% 
No. of Shares (m) (eoy)27.734.9 
Diluted no. of shares (m)34.934.9 
Diluted Earnings per share*13.217.4 
*(annualised)   

The company has launched new products including Bulaquin (an anti–malarial), Alginic Acid (a gastrointestinal), atorvastatin (a cardiovascular) and cefixime (anti–infective). These are expected to contribute to the turnover in the subsequent quarters.

The stock quotes at a price of Rs 336 which implies an earning multple of 19.3 times on the annualised earnings for FY2001.

Equitymaster requests your view! Post a comment on "Nicholas Piramal: New products make up for anti–infective decline". Click here!

  

More Views on News

PIRAMAL ENTERPRISES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY22); Net Profit Down 20.0% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (down 20.0% YoY). Sales on the other hand came in at Rs 29 bn (down 1.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Time to Buy Energy Stocks (Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

Insiders are Buying into these 6 Stocks Aggressively. More Details here... (Views On News)

Jan 19, 2022

While promoter holding is an important parameter, it should not be the sole reason for buying a stock.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jan 27, 2022 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - SHILPA MEDICARE COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS